About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Enrolling By InvitationPhase 2

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children With ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation

NCT02646839•Michael Pulsipher

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

CliniMacs TCR alpha-beta-Biotin system

Locations

11

United States

Locations (11)

Children's Hospital Los Angeles

Los Angeles, California, United States

Children's Hospital Oakland

Oakland, California, United States

Stanford University Medical Center

Palo Alto, California, United States

Rady Children's Hospital

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

Lurie Children's Hospital

Chicago, Illinois, United States

Key Dates

Start Date

October 1, 2015

Primary Completion Date

November 1, 2025

Completion Date

December 1, 2025

Last Updated

May 4, 2025

Related Studies

RECRUITINGPhase 1/2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT06303193

Myelodysplastic Syndromes

RECRUITINGEARLY Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690

Acute Lymphoblastic Leukemia

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+3 more

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

NCT06074666

Acute Lymphoblastic Leukemia, Pediatric

Familial Investigations of Childhood Cancer Predisposition

NCT03050268

Acute LeukemiaAdenomatous Polyposis+44 more

RECRUITINGPhase 1

Imetelstat Combinations in Relapsed AML

NCT07320235

Relapsed Acute Myeloid Leukemia

View all related studies

Sponsors

Lead Sponsor

Michael Pulsipher

Collaborators

University of California, San Francisco
Children's Hospital of Philadelphia
Medical College of Wisconsin
Ann & Robert H Lurie Children's Hospital of Chicago
New York Medical College
UCSF Benioff Children's Hospital Oakland
Vanderbilt University
Rady Children's Hospital, San Diego

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 4, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions